CLAIMS

1. A conjugated antibody which selectively binds either TCR beta constant region 1 (TRBC1) or TRBC2 which comprises a chemotherapeutic entity.

2. A conjugated antibody according to Claim 1, which selectively binds TRBC1.

3. A conjugated antibody according to Claim 1 or 2, which has a variable heavy chain (VH) and a variable light chain (VL) which comprise the following complementarity determining regions (CDRs):

VH CDR1: SEQ ID No. 7;

VH CDR2: SEQ ID No. 8;

VH CDR3: SEQ ID No. 9;

VL CDR1: SEQ ID No. 10;

VL CDR2: SEQ ID No. 11; and

VL CDR3: SEQ ID No. 12.

4. A conjugated antibody according to Claim 2, which comprises a variable heavy chain (VH) having the sequence shown as SEQ ID No. 1 and a variable light chain (VL) having the sequence shown as SEQ ID No. 2.

5. A conjugated antibody according to Claim 2, which comprises a scFv having the sequence shown as SEQ ID No. 3.

6. A conjugated antibody according to Claim 1, which selectively binds TRBC2.

7. A conjugated antibody according to any preceding claim, in which the chemotherapeutic entity is a cytotoxic drug.

8. A conjugated antibody according to any preceding claim for use in a method for treating a T-cell lymphoma or leukaemia in a subject.

9. A conjugated antibody for use according to Claim 8, in which the method also comprises the step of investigating the TCR beta constant region (TRBC) of a malignant T cell from the subject to determine whether it expresses TRBC1 or TRBC2.

10. A conjugated antibody for use according to Claim 8 or 9, in which the T-cell lymphoma or leukaemia is selected from peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS); angio-immunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), enteropathy-associated T-cell lymphoma (EATL), hepatosplenic T-cell lymphoma (HSTL), extranodal NK/T-cell lymphoma nasal type, cutaneous T-cell lymphoma,primary cutaneous ALCL, T cell prolymphocytic leukaemia and T-cell acute lymphoblastic leukaemia.

11. A conjugated antibody according to any of Claims 1 to 7 for use in a method for targeting the delivery of a chemotherapeutic entity to a cell which expresses either TRBC1 or TRBC2 in a subject.

12. A pharmaceutical composition which comprises a conjugated antibody according to any of Claims 1 to 7 and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

13. A method for selecting a suitable therapy to treat a subject suffering from T-cell lymphoma or leukaemia which comprises:

(i) determining whether a malignant T cell in a sample isolated from the subject expresses TRBC1 or TRBC2; and

(ii) selecting a therapy comprising a conjugated antibody according to any of Claims 1 to 7 based on the TRBC1 or TRBC2 expression of the malignant T cell.

14. A method for selecting a subject suffering from T-cell lymphoma or leukaemia to receive a therapy comprising a conjugated antibody according to any of Claims 1 to 7, which comprises:

(i) determining whether a malignant T cell in a sample isolated from the subject expresses TRBC1 or TRBC2; and

(ii) selecting the subject to receive a therapy comprising a conjugated antibody according to any of Claims 1 to 7 based on the TRBC1 or TRBC2 expression of the malignant T cell.